Inquiry Basket
7-Ethyl-10-hydroxycamptothecin - CAS 86639-52-3 Catalog number: BADC-00841
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
SN-38 (NK012) is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 (NK012) inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively.
Category
ADCs Cytotoxin
Product Name
7-Ethyl-10-hydroxycamptothecin
CAS
86639-52-3
Catalog Number
BADC-00841
Molecular Formula
C22H20N2O5
Molecular Weight
392.40
Target
Ordering Information
| Catalog Number | Size | Price | Quantity |
|---|---|---|---|
| BADC-00841 | 1 g | $199 |
Description
SN-38 (NK012) is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 (NK012) inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively.
Synonyms
(4S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)dione; 7-Ethyl-10-hydroxycamptothecin; 10-Hydroxy-7-ethylcamptothecin; SN 38 Lactone; USP Irinotecan Related Compound B; Irinotecan USP Related Compound B; NSC-673596
IUPAC Name
(19S)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
Canonical SMILES
CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)O
InChI
InChI=1S/C22H20N2O5/c1-3-12-13-7-11(25)5-6-17(13)23-19-14(12)9-24-18(19)8-16-15(20(24)26)10-29-21(27)22(16,28)4-2/h5-8,25,28H,3-4,9-10H2,1-2H3/t22-/m0/s1
InChIKey
FJHBVJOVLFPMQE-QFIPXVFZSA-N
Density
1.51±0.1 g/cm3 (Predicted)
Solubility
Soluble in DMSO (Slightly, Sonicated), Methanol (Slightly, Heated, Sonicated)
Melting Point
>169°C (dec.)
LogP
2.34760
Mechanism Of Action
The entrapment of SN-38 in lipsomes results in a more stable and more soluble form of the drug. This allows for increased affinity of SN-38 to lipid membranes and improved delivery of the drug to tumor sites. SN-38 is a highly effective cytotoxic topoisomerase I inhibitor.
Pharmacology
SN-38 (7-ethyl-10-hydroxycamptothecin) is the active metabolite of Irinotecan (CPT-11). Irinotecan is a topoisomerase I inhibitor commercially available as Camptosar®. SN-38 has been found to be 200-2000 times more cytotoxic than CPT-11, but has not been used as an anticancer drug due to its poor solubility in pharmaceutically acceptable solvents and low affinity to lipid membranes. SN-38 also undergoes a reversible conversion to an inactive open lactone ring structure at physiological pH. LE-SN-38 is a novel lipsome based formulation containing liposomes of uniform size distribution (<200 nm). Drug entrapment efficiency of the formulation is>95%.
Clinical Trial Information
| NCT Number | Condition Or Disease | Phase | Start Date | Sponsor | Status |
|---|---|---|---|---|---|
| NCT03824899 | Locally Advanced Rectal Cancer | Not Applicable | 2019-01-31 | Fudan University | Unknown Verified January 2019 by Zhu Ji, Fudan University. Recruitment status was Recruiting |
| NCT01251926 | Neoplasms | Phase 1 | 2019-11-15 | National Cancer Institute (NCI) | Completed |
| NCT02662959 | Stomach Neoplasms | Phase 2 | 2016-01-26 | Fudan University | Unknown Verified November 2015 by Weijian Guo, Fudan University. Recruitment status was Recruiting |
| NCT00311610 | Colorectal Cancer | Phase 2 | 2016-06-29 | Alliance for Clinical Trials in Oncology | Completed |
| NCT04209595 | Small Cell Lung Cancer | Phase 1, Phase 2 | 2021-09-29 | National Cancer Institute (NCI) | Suspended (Pending approval of amendment) |
Application
the treatment of colorectal cancer
Appearance
Pale Yellow to Light Yellow Solid
Purity
≥95%
Quantity
Grams-Kilograms
Shipping
Room temperature, or blue ice upon request.
Storage
Store at -20°C
Pictograms
Acute Toxic; Health Hazard
Signal Word
Danger
Boiling Point
810.3±65.0°C (Predicted)
Form
Solid
1.Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy.
Yu QQ1, Qiu H1, Zhang MS1, Hu GY1, Liu B1, Huang L1, Liao X1, Li QX1, Li ZH1, Yuan XL1. World J Gastroenterol. 2016 Apr 28;22(16):4250-8. doi: 10.3748/wjg.v22.i16.4250.
AIM: To examine the predictive effects of baseline serum bilirubin levels and UDP-glucuronosyltransferase (UGT) 1A1*28 polymorphism on response of colorectal cancer to irinotecan-based chemotherapy.
2.A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma.
Bowles DW1, Kochenderfer M2, Cohn A3, Sideris L4, Nguyen N5, Cline-Burkhardt V6, Schnadig I7, Choi M8, Nabell L9, Chaudhry A10, Ruxer R11, Ucar A12, Hausman D13, Walker L13, Spira A14, Jimeno A15. Clin Colorectal Cancer. 2016 Mar 31. pii: S1533-0028(16)30029-9. doi: 10.1016/j.clcc.2016.03.004. [Epub ahead of print]
BACKGROUND: The phosphotidylinositol-3 kinase (PI3K)/serine-threonine kinase/mammalian target of rapamycin signaling pathway is frequently altered in colorectal cancer (CRC). PX-866 is an oral, irreversible, pan-isoform inhibitor of PI3K. This randomized phase II study evaluated cetuximab with or without PX-866 in patients with metastatic, anti-epidermal growth factor receptor-naive, KRAS codon 12 and 13 wild-type CRC.
3.Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients.
Mbatchi LC1,2,3, Robert J4, Ychou M2,5, Boyer JC1, Del Rio M2, Gassiot M1,2, Thomas F6, Tubiana N7, Evrard A8,9,10. Clin Pharmacokinet. 2016 Apr 26. [Epub ahead of print]
BACKGROUND AND OBJECTIVES: Nuclear receptors PXR (pregnane X receptor, NR1I2) and CAR (constitutive androstane receptor, NR1I3) are key regulators of irinotecan metabolism, and ligand-dependent modulation of their activity leads to significant drug-drug interactions. Because genetic polymorphisms can also affect the activity of these xenobiotic-sensing receptors, we hypothesized that they could contribute to the interpatient variability of irinotecan pharmacokinetics and to the toxicity of irinotecan-based regimens.
4.The contribution of pharmacogenetics to pharmacovigilance.
Bondon-Guitton E1, Despas F2, Becquemont L3. Therapie. 2016 Mar-Apr;71(2):223-8. doi: 10.1016/j.therap.2016.02.005. Epub 2016 Mar 3.
Since the beginning of this century, information on pharmacogenetics appears in the summary of product characteristics (SPC) of drugs. Pharmacogenetic tests particularly concern the enzymes involved in the metabolism of drugs, among which P450 cytochromes. Some patients known as poor metabolisers eliminate some drugs more slowly, causing overdoses and adverse drug reactions (ADRs). The best-known examples are AVK and VKORC1-CYP2C9 or clopidogrel and CYP2C19. In the USA, the tests are recommended before the introduction of these drugs to prevent the occurrence of ADRs. Other tests are also commonly performed to address the toxicity of certain anticancer drugs (DPYD-capecitabine, UGT1A1-irinotecan, TPMT 6-mercaptopurine). Pharmacogenetic testing is also available to identify HLA loci that are very strongly associated with the occurrence of immuno-allergic reactions to a specific drug. The best-known example is HLA-B*5701, strongly associated with hypersensitivity to abacavir, and this test is now always prescribed before the instatement of this drug.
Related Products
Historical Records: Doxorubicin hydrochloride | Idarubicin | Rebeccamycin | Trastuzumab emtansine | Methotrexate disodium | Methotrexate | Duocarmycin SA | DM4-SMCC | Piericidin A | INNO-206 | 7-Ethyl-10-hydroxycamptothecin
